Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1711 - FGFR pathway genomic aberrations and response to FGFRs inhibitors


11 Sep 2017


Poster display session


Translational Research


Marjorie Faure


Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390


M. Faure1, A. Hollebecque1, R. Bahleda1, J. Soria1, V. Dyevre2

Author affiliations

  • 1 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 2 Biostatistics And Epidemiology, Institut Gustave Roussy, 94800 - Villejuif/FR


Abstract 1711


Fibroblast growth factor receptors (FGFRs) are broadly distributed transmembrane tyrosine kinase receptors. They promote cell development, differentiation, survival, migration, angiogenesis, and carcinogenesis. Specific FGFR aberrations was observed in certain cancers, some are known to be driver for tumor progression, and related to prognosis or sensitivity to cancer treatments. It is consistent to hypothesize that targeting these cancers with FGFR inhibitors would be therapeutically beneficial.


We lead a retrospective, descriptive, monocentric study, involving results of three phase I trials of Institut Gustave Roussy, for patients with refractory various solid tumors, previous selected on FGFR abnormality (amplification, single nucleotid variant (SNV), translocation). Primary endpoint was tumor response. Secondary endpoints were difference in tumor according to the type of mutation, and time to failure (TTF).


55 patients with median age of 55 years and various solid tumors were enrolled between February 16, 2011 and October 26, 2016. All patients had advanced or metastatic cancer with a median of 3.5 metastatic sites. They were heavily pretreated, in median 3 prior regimens of chemotherapy, 0 to 2 lines of targeted therapy, and one patient had immunotherapy. For patients with FGFR fusion proteins, 43% achieved partial response (PR). Median tumor response was - 46%, sustained response until 17 months. Response of SNV group depended on the type of mutation and degree of pathogenicity, in the different tumor locations. 20% had PR. Whereas some pathogenic mutations lead to dramatic response until 18 months; others failed to achieve tumor shrinkage or stabilization. 5% of patient with FGFR amplification had tumor response for 3 months only. Main clinical and biological toxicities were grade ½ and resolved after interruption. Treatment was resumed, at same or lower dose, excepted for 3 patients with permanently discontinuation. There was no death due to toxicity.


We identified genetic alterations in various members of the FGF/FGFR system that represent suitable predictive biomarkers to guide patient selection for treatment with selective pan FGFRs targeting agents.

Clinical trial identification

Legal entity responsible for the study

Institut Gustave Roussy




A. Hollebecque, R. Bahleda, J-C. Soria: Amgen, Astellas, Astra Zeneca, Bayer, Cellgene, Genentech, Ipsen, Jansen, Lilly, Novartis, Pfizer, Roche, Sanofi Aventis All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.